Today’s topic is a big one: the BIOSECURE Act, signed into law on December 18, 2025, as part of the FY 2026 National Defense Authorization Act. The law restricts federal agencies, contractors, and grant recipients from procuring or using biotechnology equipment or services from what the statute calls “biotechnology companies of concern.” This is more than a procurement rule—it has broad implications for biopharma, device companies, CDMOs, CROs, genomics companies, and even research institutions relying on federal funds. Implementation timelines, designations, and compliance obligations are already starting to take shape.
